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Introduction
Dysphagia and obstruction are among the most common indi-
cations for upper gastrointestinal endoscopy in African coun-
tries [1]. In a survey conducted by the European Society of Gas-
trointestinal Endoscopy (ESGE) International Affairs Working
Group (IAWG), benign esophageal strictures as well as malig-
nant upper gastrointestinal obstruction were reported as some
of the most prevalent diseases leading to gastrointestinal
endoscopy [1].
Management of esophageal obstruction may vary, depend-
ing on the cause of obstruction as well as the availability of re-
sources. According to the ESGE original guideline, it could in-
volve, for example, stent placement, radiotherapy/brachyther-
apy, or bypass surgery [2]. For resource-limited settings, how-
ever, a number of additional factors need to be considered be-
fore recommendations can be made. These involve economic
considerations and resource availability. Furthermore, patients
in low-resource settings presenting with malignant esophageal
obstruction are often unfit for surgery due to presentation with
advanced malignant disease as well as comorbidities such as
HIV/AIDS and tuberculosis [3]. For such situations, self-expand-
ing metal stents (SEMS) of the esophagus may provide a suita-
ble palliative option [3, 4].
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After the initial ESGE cascade guidelines on non-variceal up-
per gastrointestinal bleeding (NVUGIH), we aimed this ESGE
cascade guideline to standardize management of esophageal
stenting for benign and malignant disease in low-resource set-
tings [2, 5].
Methods
The cascade guideline methodology used has been described in
previous cascade guideline papers [1, 5]. Briefly, resource-sen-
sitive recommendations were selected from the original ESGE
guideline on esophageal stenting, but only those with an agree-
ment of 50% or more for classification as being resource-sensi-
tive by the International Affairs Working Group (IAWG) were in-
cluded in the revision process [2]. This process was guided by
six African experts from Ghana, Nigeria, and Ethiopia.
Subsequently, the IAWG, together with the first author of
the original guideline, suggested a revision of the statements
according to cascade methodology, for four predefined levels
of resource availability (▶Table 1) [6]. A modified Delphi pro-
cess was then carried out with a panel of African gastroenterol-
ogists who were invited from a contact list of ESGE, WEO, and
European national societies [1, 6]. If a 75% agreement was
reached for all four levels of care (adaptations), the statement
was accepted [6]. If the panel members disagreed with one of
the adaptations, they had the opportunity to add a comment;
thus, if an adaptation failed to reach agreement from 75% of
the panel, the statement was revised according to the advice
from the panel members. Subsequently, a second Delphi round
might be conducted to reach an agreement on all of the re-
source-sensitive statements. Furthermore, if any panel mem-
ber was unable to respond to specific statements during the
Delphi process, they could refuse to answer.
Cascade statements
Statement selection
Of the 18 recommendations in the original ESGE guideline, 11
were selected as being resource-sensitive by the IAWG. Four
adapted cascade statements – one for each level – were cre-
ated for each of the original recommendations, making a total
of 44 adapted cascade guideline statements.
The Delphi process
Overall, 19 experts participated in the Delphi process. Details of
the participants are provided in ▶Table2. A ≥75% agreement
was achieved for 41 of 44 proposed adaptations. Overall, three
cascade adaptations of three recommendations involving sur-
gery as an alternative form of treatment for malignant obstruc-
tion failed to achieve the ≥75% agreement level. Following the
advice from the panel of experts, these statements underwent
further revision as described below.
▶ Table 1 Level of treatment care.
Predefined level Definition
I: Basic Core resources or fundamental services absolutely necessary for an endoscopy care system to function. By definition, a health
care system lacking any basic level resource would be unable to provide endoscopic service to its patient population. It includes
diagnostic procedures (gastroscopy and colonoscopy) as well and fundamental monitoring abilities (blood pressure, basic
blood biochemistry).
II: Limited Limited level: Second-tier resources or services that produce major improvements in outcome, such as increased survival, but
that are attainable with limited financial means and modest infrastructure. It includes minor endoscopic procedures to im-
prove major clinical outcomes (i. e. sclerotherapy/adrenaline injection, band ligation, plasma expanders, basic surgical inter-
ventions).
III: Enhanced Enhanced level: Third-tier resources or services that are optional but important. Enhanced-level resources may produce minor
improvements in outcome but increase the number and quality of therapeutic options. Most procedures that improves clinical
outcome are available (i. e. biliopancreatic endoscopy, electrosurgical unit, polypectomy/mucosectomy, anesthesia back-up).
IV: Maximal Maximal level: High-level resources or services that may be used in some high-resource countries or be recommended in
guidelines that assume unlimited resources. To be useful, maximal-level resources typically depend on the existence and
functionality of all lower-level resources.
▶ Table 2 Characteristics of participants in the Delphi analysis.
Number of participants (n=19)
Geographical area
▪ North Africa (%) 3 (16)
▪ Central Africa (%) 3 (16)
▪ East Africa (%) 6 (32)
▪ West Africa (%) 6 (32)
▪ South Africa (%) 1 (5)
Socioeconomic status of institution/hospital
▪ High (%) 0 (0)
▪ Mid (%) 8 (42)
▪ Low (%) 11 (58)
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▶ Table 3 Statements and recommendations.
1. ESGE recommends placement of partially or fully covered self-expanding metal stents (SEMSs) for palliation of malignant dysphagia over laser
therapy, photodynamic therapy, and esophageal bypass (strong recommendation, high-quality evidence).
I. Best supportive care/palliative care
II. Surgery
III. SEMS
3. For patients with longer life expectancy, ESGE recommends brachytherapy as a valid alternative or in addition to stenting in oesophageal cancer
patients with malignant dysphagia. Brachytherapy may provide a survival advantage and possibly a better quality of life compared to SEMS place-
ment alone. (Strong recommendation, high-quality evidence.)
I. Best supportive care/palliative care
II. Surgery
III. SEMS
4. Esophageal SEMS placement is recommended as the preferred treatment for sealing malignant tracheoesophageal or bronchoesophageal fistula
(strong recommendation, low-quality evidence).
I. Best supportive care/palliative care
II. Surgery
III. SEMS
5. Application of double stenting (oesophagus and airways) can be considered when fistula occlusion is not achieved by esophageal or airway
prosthesis alone (strong recommendation, low-quality evidence).
I. Best supportive care/Palliative care
II. Best supportive care
III. Oesophageal stenting
8. ESGE suggests that SEMS placement with concurrent single-dose brachytherapy is safe and effective for relief of dysphagia (weak recommendation,
low-quality evidence).
I. Best supportive care/palliative care
II. Surgery
III. SEMS
10. ESGE suggests consideration of temporary placement of self-expandable stents for refractory benign oesophageal strictures (weak recommen-
dation moderate quality evidence).
I. Symptomatic treatment/best supportive care
II. Bougienage, ballon dilation, or surgery
III. SEMS
13. ESGE suggests that FCSEMSs be preferred over PCSEMSs for treatment of refractory benign esophageal stricture, because of their lack of embed-
ment and ease of removability (weak recommendation, low-quality evidence).
I. Symptomatic treatment, best supportive care
II. Bougienage, ballon dilation, or surgery
III. FCSEMS
14. ESGE recommends the stent-in-stent technique to remove PCSEMSs that are embedded in the esophageal wall (strong recommendation, low
quality evidence).
I. Symptomatic treatment, best supportive care
II. Attempt to remove PCSEMSs using conventional methods such as rat tooth forceps or APC
III. Stent-in-stent technique
16. If refractory benign esophageal stricture has not satisfactorily improved after two separate treatments with temporary stenting, ESGE suggests
alternative treatment strategies such as self-dilation or surgical treatment (weak recommendation, low quality evidence). In poor surgical candi-
dates, ESGE recommends self-dilation with rigid dilators (strong recommendation, low quality evidence).
I. Symptomatic treatment, best supportive care
II. Bougienage, surgery
III. Self-dilation
17. ESGE recommends that temporary stent placement can be considered for treatment of leaks, fistulas, and perforations. No specific type of stent
can be recommended and duration of stenting should be individualized. (Strong recommendation, low-quality of evidence).
I. Symptomatic treatment, antibiotics, nill by mouth, or fluid diet
II. Endoscopic closure attempt with clips, or surgery
III. Stent placement
18. ESGE recommends considering placement of a SEMS for treatment of esophageal variceal bleeding refractory to medical, endoscopic, and/or
radiological therapy, or as initial therapy for patients with massive bleeding (strong recommendation, moderate quality evidence).
I. Supportive care
II. Supportive care
III. Stent placement
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Cascade adaptation
Each original recommendation with the accepted adaptations is
reported in ▶Table3. The main resources that influenced
adaptation of the original guidelines can be categorized as fol-
lows:
Malignant strictures
In many impoverished parts of Africa, malignant esophageal
strictures are more often diagnosed in an advanced stage of
disease [7]. For advanced tumor stages, palliative surgical op-
tions may be more readily available than stenting for treatment
of malignant esophageal strictures.
At the basic level, only best supportive care is available and
palliative treatment such as nasogastric feeding tubes or intra-
venous fluid supply may be the only available option.
At the limited level, treatment of symptomatic cancer varies
from region to region, mainly depending on availability of sur-
gery as a treatment option. Surgery can be offered to patients
with resectable tumors and longer life expectancy who are fit
enough to undergo surgery.
Stent placement should be offered to patients where the
necessary infrastructure and expertise are available, usually at
the enhanced level.
Additional barriers are represented by the following factors:
1. Training – lack of availability of expert gastroenterologists
with the necessary technical skills for stent placement.
2. Infrastructure – lack of availability of stents, fluoroscopy,
and other equipment involved in stent placement. Further-
more, lack of availability of brachytherapy/radiotherapy for
treatment of malignant strictures.
Benign strictures
The most common causes of benign strictures in African coun-
tries include corrosive and peptic aetiologies as well as achala-
sia [8, 9].
Similar to treatment of malignant strictures, the lack of both
surgery and endoscopy resources will hinder clinically relevant
treatment at the basic level. On the other hand, at the limited
level, periodic endoscopic dilation may be an affordable option.
Also, surgical treatment should be considered, depending on
its availability.
Conclusions
Most of the original recommendations for esophageal stenting
of malignant and benign disease were successfully adapted to a
cascade approach for resource-limited areas. The cascade
guidelines addressed limitations that were related to infra-
structural and human resources. For example, at the basic level,
neither SEMS nor skilled gastroenterologists are available for
treatment of esophageal strictures, therefore, best supportive
care may be the only reasonable alternative. And even when ex-
pert gastroenterologists are available, technological resources
such as fluoroscopy or brachytherapy may limit treatment of
such patients. Palliative surgery may be an alternative, but also
associated with extensive use of resources and presumably with
high mortality. Finally, even when resources and expertise are
available for endoscopic stenting or surgery, patients and their
families may not be able or willing to pay for the high financial
costs involved.
Two major limitations of the Delphi process need to be high-
lighted:
1. The total number of participants was low especially com-
pared to the first ESGE cascade guideline on NVUGIH [5].
2. Some participants may have had limited experience and ex-
pertise in treatment of esophageal strictures or in the use of
esophageal stents and brachytherapy/radiotherapy. This was
reflected in the high number of total “don’t know” answers
(97 /627) given by the participants.
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